Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
CSK Antibody
Purified Mouse Monoclonal Antibody (Mab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB, ICC |
|---|---|
| Primary Accession | P41240 |
| Reactivity | Human |
| Host | Mouse |
| Clonality | Monoclonal |
| Isotype | IgG2b |
| Calculated MW | 50 KDa |
| Gene ID | 1445 |
|---|---|
| Other Names | C SRC;C SRC kinase;C src Tyrosine Kinase;C-SRC kinase;c-src tyrosine kinase;Csk A;CSK; CSK_HUMAN;CYTOPLASMIC TYROSINE KINASE;EC 2.7.10.2;MGC112926;MGC117393;MGC154049;P60 Src; Protein tyrosine kinase CYL;Protein-tyrosine kinase CYL;Proto oncogene tyrosine protein kinase;Tyrosine protein kinase CSK;Tyrosine protein kinase CSK;Tyrosine-protein kinase CSK;zgc:154049. |
| Dilution | WB~~1:1000 ICC~~1:50 |
| Format | Purified mouse monoclonal in buffer containing 0.1M Tris-Glycine(pH 7.4,150 mM NaCl)with 0.09% (W/V) sodium azide,0.1mg/mlBSA and 50% glycerol. |
| Storage | Store at -20 °C.Stable for 12 months from date of receipt |
| Name | CSK |
|---|---|
| Function | Non-receptor tyrosine-protein kinase that plays an important role in the regulation of cell growth, differentiation, migration and immune response. Phosphorylates tyrosine residues located in the C- terminal tails of Src-family kinases (SFKs) including LCK, SRC, HCK, FYN, LYN, CSK or YES1. Upon tail phosphorylation, Src-family members engage in intramolecular interactions between the phosphotyrosine tail and the SH2 domain that result in an inactive conformation. To inhibit SFKs, CSK is recruited to the plasma membrane via binding to transmembrane proteins or adapter proteins located near the plasma membrane. Suppresses signaling by various surface receptors, including T-cell receptor (TCR) and B-cell receptor (BCR) by phosphorylating and maintaining inactive several positive effectors such as FYN or LCK. |
| Cellular Location | Cytoplasm. Cell membrane. Note=Mainly cytoplasmic, also present in lipid rafts |
| Tissue Location | Expressed in lung and macrophages. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Non-receptor tyrosine-protein kinase that plays an important role in the regulation of cell growth, differentiation, migration and immune response. Phosphorylates tyrosine residues located in the C-terminal tails of Src-family kinases (SFKs) including LCK, SRC, HCK, FYN, LYN or YES1. Upon tail phosphorylation, Src-family members engage in intramolecular interactions between the phosphotyrosine tail and the SH2 domain that result in an inactive conformation. To inhibit SFKs, CSK is recruited to the plasma membrane via binding to transmembrane proteins or adapter proteins located near the plasma membrane. Suppresses signaling by various surface receptors, including T- cell receptor (TCR) and B-cell receptor (BCR) by phosphorylating and maintaining inactive several positive effectors such as FYN or LCK.
References
Partanen J.,et al.Oncogene 6:2013-2018(1991).
Braeuninger A.,et al.Proc. Natl. Acad. Sci. U.S.A. 88:10411-10415(1991).
Brauninger A.,et al.Gene 110:205-211(1992).
Braeuninger A.,et al.Oncogene 8:1365-1369(1993).
Halleck A.,et al.Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
